Allogeneic peripheral blood progenitor cell (PBPC) transplants are an alternative to BMT, although G-CSF mobilization dose, timing of pheresis and risk of GVHD are not well defined. We compared harvest characteristics, donor and recipient outcomes and costs of two PBPC transplant strategies with historical controls who received BMT. Twenty donors mobilized with four daily s.c. G-CSF doses (5 g/kg/day) (group 1) and 20 mobilized with 10 g/kg/day G-CSF (group 2) were compared with 20 BM controls (group 3). G-CSF and phereses were well tolerated. Four of 40 PBPC donors required femoral catheter placement. At least 2.5 × 10 6 CD34 + /kg recipient weight were collected with two phereses in 19/20 donors (group 1) and 18/20 donors (group 2). Time to neutrophil (18 vs 20 vs 22 days, P = 0.02) and platelet (21 vs 24 vs 27 days, P = 0.005) engraftment was shorter in the PBPC groups (group 2 vs group 1 vs group 3) but secondary engraftment outcomes were not different. The incidence of grade 2-4 aGVHD was higher in the low-dose G-CSF group (group 1) but there was no difference in cGVHD, 100-day or 1-year survival. The mean PBPC transplant cost (group 1) at first hospital discharge was less than BM (group 3) ($34 643 vs $37 354) but the mean overall cost for both groups was similar at 100 days ($46 334 vs $46 083). Allogeneic PBPC transplant with short course, low-dose G-CSF mobilization is safe, feasible and cost equivalent to allogeneic BMT. Keywords: economic analysis; allogeneic peripheral blood transplant Hematopoietic progenitor cells which are capable of reestablishing hematopoiesis after myeloablative chemotherapy circulate in the peripheral blood in low numbers.
which they can be efficiently collected with one or more phereses and be used to successfully re-establish hematopoiesis after re-infusion. 3, 4 In autologous transplantation, PBPC transplants result in faster neutrophil and platelet engraftment, less antibiotic and blood product use and shorter hospitalizations compared to bone marrow (BM) transplants. 5 More recently, PBPC collected from normal donors following treatment with granulocyte colony-stimulating factor (G-CSF) have been used in allogeneic transplantation. Several single center studies report that G-CSF mobilized allogeneic PBPC transplants are safe, well tolerated and result in faster neutrophil and platelet engraftment compared to historical BM controls. [6] [7] [8] The optimal dose and duration of G-CSF priming, the number and timing of phereses and the minimum number of leukocytes, CD34
+ cells or colony-forming unit (CFU) cells required for allogeneic engraftment are not known. In addition, allogeneic PBPC harvests contain 10-fold more T cells than BM harvests and this may lead to more graftversus-host disease (GVHD). Most, [6] [7] [8] [9] [10] [11] though not all, 12 studies have found a similar incidence and severity of GVHD following PBPC or BM transplant but the published case series are small and limited by retrospective comparison with historical controls. We report the results of a pilot study of allogeneic PBPC transplantation designed to assess the safety, feasibility and economic costs of two PBPC mobilization strategies. We compared the clinical and economic outcomes of allogeneic PBPC transplants using two doses of G-CSF (group 1, n = 20: 5 g/kg/day; group 2, n = 20: 10 g/kg/day) with allogeneic BM transplants as historical controls (group 3, n = 20). This study was undertaken in preparation for a larger Canadian multicenter randomized comparison of allogeneic PB and BM transplantation which is currently accruing patients. 13 
Patients and methods

PBPC donors
PBPC donors were 5/6 or 6/6 HLA-matched first-degree relatives of the recipients. Donors received four daily subcutaneous G-CSF injections (group 1: 5 g/kg/day; group 2: 10 g/kg/day) rounded to the nearest vial size (300 g, 480 g, 600 g, etc).
PBPC collection and processing
Apheresis of 6-13 l blood using a Cobe Spectra (Cobe, Lakewood, CO, USA) blood cell separator was performed on 2 consecutive days, beginning on the day of the fourth G-CSF dose. Donor venous access was obtained using peripheral veins or, if required, a temporary femoral vein catheter. Collection from the first pheresis was stored overnight at room temperature without agitation. Both collections were infused into the recipient after the second pheresis through a central venous catheter without an in-line blood filter.
All donors underwent at least two phereses. If 2.5 × 10 6 CD34 + cells/kg recipient weight (rw) were not collected with two phereses, the donor underwent a third pheresis and/or BM harvest. All collections from the donor were infused into the recipient and PBPC collections were not red cell-depleted or cryopreserved.
BM harvest
BM was collected from the posterior iliac crests as previously described. 14 The harvest was completed when at least 2 × 10 8 WBC/kg rw, but not more than 1.3 l of BM, were collected.
Preparative regimen and supportive care
Recipients were conditioned with chemotherapy with or without radiation according to their diagnosis and disease status (Table 1) and nursed in single laminar flow HEPAfiltered rooms. Post-transplant prophylactic antibiotics, antifungal prophylaxis and growth factors were not used. Patients who were herpes simplex virus antibody positive received acyclovir prophylaxis (400 mg p.o. twice daily or 80 mg i.v. twice daily) from day +1 until day +28. Broad spectrum antibiotics were administered when neutropenic patients (absolute neutrophil count Ͻ0.5 × 10 9 /l) became 
Evaluation and definitions
The WBC, CD34
+ and colony-forming unit (CFU-GM, CFU-GEMM, BFU-E, CFU-Mega) cell content of PBPC collections and WBC and CFU cell content of BM collection were assayed on the day of collection. WBC counts were measured using an automated Coulter counter (Coulter, Hialeah, FL, USA) and verified visually. CD34 + cells were measured according to the method of Sutherland et al 15 and CFU progenitor cell assays were performed as previously described. 14 Neutrophil engraftment was defined as the second of 2 days with an ANC Ͼ0.5 × 10 9 /l and platelet engraftment as the second of 2 days with a platelet count Ͼ20 × 10 9 /l not due to platelet transfusion. Duration of first hospitalization was measured from the day of PBPC or BM infusion until the day of first discharge. GVHD was graded according to published criteria. 16, 17 Recipient outcomes in the two PBPC transplant groups (groups 1 and 2) were compared with historical controls who had undergone allogeneic BM transplant between 1991 and 1995. Controls were matched with cases for age (within 10 years), diagnosis and conditioning regimen.
Economic analysis
The first 10 PBPC transplant recipients in the low-dose G-CSF group (group 1) were matched by age, diagnosis and conditioning regimen on a 1 to 2 basis with 20 BM transplant controls. A cost minimization analysis was then conducted from a Canadian health care system perspective to compare the overall cost of PBPC and BM transplant from the first day of chemotherapy until 100 days post-transplant. The analysis included direct expenditure for hospitalization, conditioning chemotherapy, supportive care, antibiotics, laboratory tests, bronchoscopy, physician fees and all related donor costs.
The costs used in this study were obtained from the Princess Margaret Hospital (PMH), a large cancer treatment center located in Toronto, Ontario, Canada. The cost of PBPC and BM collection, including personnel and supplies, were obtained from the Department of Ambulatory Services, along with nursing workload measurement statistics. Supportive care expenditures, laboratory tests and patient monitoring costs were provided from the Departments of 
Statistical methods
Laboratory and clinical data are reported as medians with a corresponding range and number of observations. The economic data are presented as means with appropriate 95% confidence intervals (CI). Differences between median values were evaluated for statistical significance using the Kruskal-Wallis test. Correlation analyses were performed using the Spearman rank test. Actuarial estimates of time to engraftment were calculated according to the method of Kaplan and Meier and comparisons of time to engraftment were made using the Wilcoxon test.
Results
PBPC donors
PBPC donors tolerated G-CSF administration at 5 g/kg/day (group 1) and 10 g/kg/day (group 2) with only mild myalgias and arthralgias. All donors experienced a rise in their peripheral blood WBC count (median 43.8 × 10 9 /l, range 15.2-61.5 × 10 9 /l, n = 39) and a decrease in platelet count (median 168 × 10 9 /l, 71-290 × 10 9 /l, n = 39). None experienced evidence of leukostasis or bleeding. + cells/kg rw and 1/40 donor (group 1) underwent a third pheresis and bone marrow harvest. In two of four cases, there was a significant weight discrepancy between the donor and recipient and in one of four cases, the donor had a moderate pancytopenia and although his bone marrow prior to PBPC collection was normal, there was a history of significant alcohol use. The PBPC and BM collection characteristics are shown in Table 2 . For each PBPC group (groups 1, 2), the median WBC/kg rw, CD34 + /kg rw and CFU cell/kg rw was higher on the second day of pheresis than on the first. The median WBC/kg rw, CD34 + /kg rw and CFU cell/kg rw were higher in donors receiving 10 g/kg/day G-CSF (group 2) than in those receiving 5 g/kg/day (group 1). The median CFU cell/kg rw content of the BM harvests was higher than either of the PBPC harvest groups.
Engraftment
Fifty-nine of 60 recipients had successful neutrophil engraftment with one death prior to neutrophil engraftment (group 1). Fifty-eight of 60 recipients had successful platelet engraftment and two died prior to platelet engraftment (group 1: 1, group 2: 1). Recipient engraftment times and engraftment-dependent outcomes are shown in Table 3 .
There was a statistically significant shortening of time to neutrophil (group 2 vs 1 vs 3; P = 0.02) and platelet engraftment (group 2 vs 1 vs 3; P = 0.005) in the PBPC groups compared to the BM group.
Secondary engraftment-dependent outcomes including number of platelet and red cell transfusions, febrile days, days on antibiotics, days to first hospital discharge and days in hospital during the first 60 days post-transplant were not statistically significantly different among the three groups (Table 3) .
There was a statistically significant correlation between WBC/kg rw content of the collections and time to neutrophil (r = −0.26, P = 0.05) and platelet engraftment (r = −0.28, P = 0.04) when all three groups were considered together. There were no statistically significant correlations between CD34
+ cell/kg rw and CFU/kg rw content of the collections and time to neutrophil and platelet engraftment (Table 4) . No significant correlation between these product characteristics and the time to neutrophil and platelet engraftment was seen when the three groups were analyzed separately or together. There was a significant correlation between the product WBC content and its corresponding CD34 + (r = 0.60, P = 0.0001, n = 40) and CFU-GM (r = 0.78, P = 0.0001, n = 35) content.
GVHD
Each group received the same median number of methotrexate doses (median, range; group 1: 3, 2-4, n = 20; group 2: 3, 0-4, n = 20; group 3: 3, 0-4, n = 20). Six of 60 (10%) patients were not assessable for GVHD due to early death (group 1: 3, group 2: 2, group 3: 1). The incidence of GVHD is shown in Table 5 . There was a statistically sig- nificant higher incidence of aGVHD in group 1 compared to groups 2 and 3 (P = 0.006), but no difference in the incidence of cGVHD among the three groups (P = 0.53).
Survival
As of February 1998, the median follow-up was 224 days (range 25-582), 261 days (range 18-414) and 750 days (48-1749) for groups 1, 2 and 3, respectively. The 100-day mortality was not statistically significantly different between the three groups: 3/20 (15%) group 1, 2/20 (10%) group 2 and 1/20( 5%) group 3. The overall survival at 1 year was: 9/16, 56% group 1; 16/18, 88% group 2, and 13/20, 65% group 3.
Economic analysis
The first 10 patients in 5 g/kg/day PBPC group (group 1) were matched with 20 patients in the BM group (group 3).
Costs from admission until discharge and from discharge until 100 days post-transplant were assessed separately and then combined ( Table 6 ). The mean cost to first discharge was $34 643 in the PBPC group and $37 354 in the BM group. Following discharge from hospital, patients in each group were followed to 100 days post-transplant or death, whichever came first. Health care resource data collected up to that time included costs for hospital readmissions, drug prescriptions (eg cyclosporin), home antimicrobial infusions (eg ganciclovir), blood products and all related physician fees. From the day of discharge until 100 days post-transplant, the mean costs in the PBPC group were higher than in the BM group ($11 691 vs $8729) due to a higher readmission rate in the PBPC group. There were nine readmissions affecting six of the 10 patients in the PBPC group due to GVHD (4), fever/sepsis (3), CMV infection (1) and other causes (1). There were 10 readmissions affecting nine of the 20 patients in the BM group due to GVHD (1), fever/sepsis (5), CMV infection (1) and other causes (3).
In the final phase of the economic analysis, total treatment costs at discharge and up to 100 days post-transplant were combined. The overall costs were $46 334 (95% CI: $39 358-$53 310) and $46 083 (95%CI: $41 021-$51 145) in the PBPC and BM, respectively ( Table 6 ). The results imply that cost savings initially realized in PBPC patients secondary to reduced hospital stay were lost following discharge because of higher readmission rates. However, this small economic analysis is descriptive and not powered to detect statistically significant economic differences. Nevertheless, to our knowledge, this is the first economic evaluation of allogeneic PBPC and the first economic evaluation Table 6 Economic analysis: overall cost of PBPC (group 1) or BM (group 3) transplants (day 0-day 100) in both autologous and allogeneic transplantation to compare overall health care resource consumption to 100 days.
Discussion
The In this report, we compared two groups of allogeneic PBPC transplant recipients whose donors were mobilized with two doses of G-CSF with a group of matched historical BM controls. We observed a statistically significant shortening of time to neutrophil and platelet engraftment although secondary engraftment outcomes such as blood product use, febrile days and number of days on antibiotics were not statistically significantly different among the three groups. We observed a higher incidence of acute GVHD in one of the two PBPC groups in this small study (group 1). There was no difference in the incidence of chronic GVHD but follow-up is short.
There has been concern about the short-and long-term consequences of administering growth factors to normal donors. 19, 20 Our study confirms that G-CSF administration to normal donors is well tolerated and safe in the short term. Since the long-term effects of even brief courses of G-CSF are not known, we chose to study a very short course of G-CSF administration. In this study, pheresis was begun after 3 days of G-CSF and most donors had a satisfactory collection after four G-CSF doses. Although the PBPC group receiving 10 g/kg/day G-CSF (group 2) had higher WBC, CD34
+ cells and CFU cell content in the PBPC harvest compared to the 5 g/kg/day G-CSF group, as well as faster hematopoietic engraftment, the number of donors in whom we were unable to collect 2.5 × 10 6 CD34 + cells/kg rw was not different between the 5 and 10 g/kg/day groups. Thus, in this small study, the higher G-CSF dose improved the progenitor cell content of the PBPC harvest and resulted in modest shortening of neutrophil and platelet engraftment times, but did not improve clinically important secondary engraftment outcomes such as red cell or platelet transfusion requirements or days in hospital, nor did it reduce collection failure rates.
We undertook a comprehensive analysis of the PBPC progenitor cell content and, in addition to measuring WBC, CD34
+ and CFU-GM cell content of the PBPC product, also measured CFU-GEMM, BFU-E and CFU-Mega. No correlation was observed between these latter measures of progenitor cell content and engraftment times. Our small study may have lacked the power to demonstrate a correlation were it present. An alternative hypothesis is that the progenitor cell content of allogeneic PBPC harvest is above the threshold at which variations in progenitor cell content affect engraftment. Factors other than progenitor cell dose may be important co-determinants of allogeneic engraftment. The methotrexate dose administered for GVHD prophylaxis, recipient factors and the degree of genetic disparity between the donor and recipient may be as important determinants of allogeneic engraftment as minor variations in progenitor cell content of the PBPC or BM harvest.
Our study included an economic analysis of allogeneic PBPC transplant from the perspective of the Canadian health care system. We compared the costs of the first 10 allogeneic PBPC transplants (group 1) with 20 matched BM transplants (group 3). Although similar studies have been reported in the autologous setting, 21 this is the first comprehensive economic analysis of allogeneic PBPC transplantation. We found that there was no difference in the overall costs of the PBPC and BM transplantation strategies. The incremental costs of G-CSF and pheresis were offset by savings in operating room and anesthetic time. Costs attributable directly to the recipient which were incurred after day 0 did not differ between the two groups. This is expected since the major determinants of those costs (antibiotic use and duration of hospitalization) did not differ between the PBPC and BM groups.
Based on the preliminary results of this study, particularly the safety and efficacy of the low-dose, short-duration, G-CSF-mobilization strategy, the Canadian Bone Marrow Transplant Group is undertaking a randomized multicenter study comparing allogeneic PBPC and BM transplants. 13 This and other randomized trials currently in progress should definitively address the question of whether allogeneic PBPC transplantation represents a therapeutic advance or remains a technical alternative to traditional allogeneic BM transplantation.
